Document is current
Any future updates will be listed below
-
Authors
Pinard, Maxime
Dastpeyman, Samaneh
Poitras, Christian
Bernard, Geneviève
Gauthier, Marie-Soleil
Coulombe, Benoit https://orcid.org/0000-0003-1702-0692
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (377869, 426534)
Leukodystrophy Foundation (Leukodystrophy Foundation (Québec))
- License Information
-
More Information
Article History
Received: 8 July 2022
Accepted: 16 October 2022
First Online: 30 November 2022
Declarations
:
: Not applicable.
: Not applicable.
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Dr. Bernard is/was a consultant for Passage Bio Inc (2020–2021) and Ionis (2019). She is/was a site investigator for the Alexander’s disease trial of Ionis (2021), Metachromatic leukodystrophy of Shire/Takeda (2020–2021), Krabbe and GM1 gene therapy trials of Passage Bio, and Adrenoleukodystrophy/Hematopoietic stem cell transplantation natural history study of Bluebird Bio (2019) and a site sub-investigator for the MPS II gene therapy trial of Regenxbio (2021). She has received an unrestricted educational grant from Takeda (2021). She serves on the scientific advisory board of the Pelizaeus-Merzbacher Foundation and is the Chair of the Medical and Scientific Advisory Board of the United Leukodystrophy Foundation. She is on the editorial boards of Neurology Genetics, Frontiers in Neurology – Neurogenetics, and Journal of Medical Genetics.
